Hypothermic Oxygenated Liver Perfusion (HOPE) Prevents Tumor Recurrence in Liver Transplantation From Donation After Circulatory Death.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
6
9
2020
medline:
11
11
2020
entrez:
5
9
2020
Statut:
ppublish
Résumé
The aim of this study was to investigate tumor recurrence after liver transplantation for hepatocellular carcinoma (HCC), with and without hypothermic oxygenated liver perfusion (HOPE) before transplantation. We analyzed all liver recipients with HCC, transplanted between January 2012 and September 2019 with donation after circulatory death (DCD) livers after previous end-ischemic HOPE-treatment (n = 70, Center A). Tumor parameters and key confounders were compared to consecutive recipients with HCC, transplanted during the same observation period with an unperfused DBD liver (n = 70). In a next step, we analyzed unperfused DCD (n = 70) and DBD liver recipients (n = 70), transplanted for HCC at an external center (Center B). Tumor parameters were not significantly different between HOPE-treated DCD and unperfused DBD liver recipients at Center A. One-third of patients were outside established tumor thresholds, for example, Milan criteria, in both groups. Despite no difference in tumor load, we found a 4-fold higher tumor recurrence rate in unperfused DBD livers (25.7%, 18/70), compared to only 5.7% (n = 4/70) recipients with tumor recurrence in the HOPE-treated DCD cohort (P = 0.002) in Center A. The tumor recurrence rate was also twice higher in unperfused DCD and DBD recipients at the external Center B, despite significant less cases outside Milan. HOPE-treatment of DCD livers resulted therefore in a 5-year tumor-free survival of 92% in HCC recipients, compared to 73%, 82.7%, and 81.2% in patients receiving unperfused DBD or DCD livers, from both centers. We suggest that a simple machine liver perfusion approach appears advantageous to protect from HCC recurrence after liver transplantation, despite extended tumor criteria.
Identifiants
pubmed: 32889870
doi: 10.1097/SLA.0000000000004258
pii: 00000658-202011000-00014
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
759-765Références
Selten J, Schlegel A, de Jonge J, et al. Hypo- and normothermic perfusion of the liver: Which way to go? Best Pract Res Clin Gastroenterol 2017; 31:171–179.
Schlegel AA, Kalisvaart M, Muiesan P. Machine perfusion in liver transplantation: an essential treatment or just an expensive toy? Minerva Anestesiol 2018; 84:236–245.
Kron P, Schlegel A, Muller X, et al. Hypothermic oxygenated perfusion: a simple and effective method to modulate the immune response in kidney transplantation. Transplantation 2019; 103:e128–e136.
Schlegel A, Kron P, Graf R, et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. Ann Surg 2014; 260:931–937. discussion 937-8.
Hashimoto K, Cypel M, Kim H, et al. Soluble adhesion molecules during ex vivo lung perfusion are associated with posttransplant primary graft dysfunction. Am J Transplant 2017; 17:1396–1404.
Li CX, Man K, Lo CM. The impact of liver graft injury on cancer recurrence posttransplantation. Transplantation 2017; 101:2665–2670.
Orci LA, Lacotte S, Delaune V, et al. Effects of the gut–liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. J Hepatol 2017; 68:978–985.
Lim C, Azoulay D. Ischemia–reperfusion injury and regrowth of liver cancers: to clamp or not to clamp? Dig Dis Sci 2014; 59:2030–2031.
Dutkowski P, Schlegel A, De Oliveira M, et al. HOPE for human liver grafts obtained from donors after cardiac death. J Hepatol 2014; 60:765–772.
Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transplant 2008; 14:1107–1115.
Toso C, Meeberg G, Hernandez-Alejandro R, et al. TotaL tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015; 62:158–165.
Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2017; 154:128–139.
Dutkowski P, Oberkofler CE, Slankamenac K, et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011; 254:745–753. discussion 753.
Schlegel A, Kalisvaart M, Scalera I, et al. The UK DCD Risk Score: a new proposal to define futility in donation-after-circulatory-death liver transplantation. J Hepatol 2018; 68:456–464.
Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6:783–790.
Ghinolfi D, Rreka E, Pezzati D, et al. Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2017; 2:87.
Schlegel AA, Muller X, Kalisvaart M, et al. Outcomes of liver transplantations from donation after circulatory death (DCD) treated by hypothermic oxygenated perfusion (HOPE) before implantation. J Hepatol 2019; 50–57.
Kron P, Schlegel A, Mancina L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. J Hepatol 2018; 68:82–91.
Croome KP, Lee DD, Burns JM, et al. The use of donation after cardiac death allografts does not increase recurrence of hepatocellular carcinoma. Am J Transplant 2015; 158:2704–2711.
Khorsandi SE, Yip VS, Cortes M, et al. Does donation after cardiac death utilization adversely affect hepatocellular cancer survival? Transplantation 2016; 100:1916–1924.
Croome KP, Wall W, Chandok N, et al. Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transplant 2013; 19:1214–1223.
Nagai S, Yoshida A, Facciuto M, et al. Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 2015; 61:895–904.
Kornberg A, Witt U, Kornberg J, et al. Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early hepatocellular carcinoma recurrence following liver transplantation. Aliment Pharmacol Ther 2015; 42:1101–1110.
Kornberg A, Witt U, Kornberg J, et al. Extended ischemia times promote risk of hcc recurrence in liver transplant patients. Dig Dis Sci 2015; 60:2832–2839.
Li CX, Man K, Lo CM. The Impact of Liver Graft Injury on Cancer Recurrence Posttransplantation. Transplantation 2017; 101:2665–2670.
Luo D, Wang Z, Wu J, et al. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int 2014; 2014:409272.
Jiao M, Nan KJ. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol 2012; 40:461–468.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539–545.
He G, Karin M. NF-κB and STAT3—key players in liver inflammation and cancer. Cell Res 2010; 21:159–168.
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017; 16:1Epub ahead of print 2017. DOI: 10.4103/jcar.JCar_9_16.
doi: 10.4103/jcar.JCar_9_16
Patrono D, Surra A, Catalano G, et al. Hypothermic oxygenated machine perfusion of liver grafts from brain-dead donors. Sci Rep 2019; 27:1.
Van Rijn R, Karimian N, Matton A, et al. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. Br J Surg 2017; 104:907–917.
Schlegel A, Dutkowski P. Impact of machine perfusion on biliary complications after liver transplantation. Int J Mol Sci 2018; 19:
Muller X, Schlegel A, Kron P, et al. Novel real time prediction of liver graft function during hypothermic oxygenated machine perfusion prior to liver transplantation. Ann Surg 2019; 270:783–790.
Próchnicki T, Latz E. Inflammasomes on the crossroads of innate immune recognition and metabolic control. Cell Metabolism 2017; 26:71–93.
Karki R, Man SM, Kanneganti T-D. Inflammasomes and cancer. Cancer Immunol Res 2017; 5:94–99.
Westerkamp A, Karimian N, Matton A, et al. Oxygenated hypothermic machine perfusion after static cold storage improves hepatobiliary function of extended criteria donor livers. Transplantation 2016; 100:825–835.
Schlegel A, Kron P, Graf R, et al. Warm vs. cold perfusion techniques to rescue rodent liver grafts. J Hepatol 2014; 61:1267–1275.